Detalhe da pesquisa
1.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
; 387(2): 132-147, 2022 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35660812
2.
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Blood
; 142(14): 1208-1218, 2023 10 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37366170
3.
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Lancet Oncol
; 24(7): 811-822, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37414012
4.
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Cancer
; 129(23): 3746-3760, 2023 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37622738
5.
Diagnosis and Management of Multiple Myeloma: A Review.
JAMA
; 327(5): 464-477, 2022 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35103762
6.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
N Engl J Med
; 379(10): 934-947, 2018 09 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30184451
7.
The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study.
Biol Blood Marrow Transplant
; 26(12): 2372-2377, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32846200
8.
The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma.
Ann Hematol
; 99(1): 121-126, 2020 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-31773215
9.
Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma.
J Natl Compr Canc Netw
; 17(7): 840-847, 2019 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31319391
10.
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Lancet Oncol
; 19(12): 1641-1653, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30442502
11.
Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Biol Blood Marrow Transplant
; 24(7): 1386-1391, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29481870
12.
Plasma cell diseases and organ transplant: A comprehensive review.
Am J Transplant
; 18(5): 1046-1058, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29524307
13.
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
Br J Haematol
; 183(4): 601-607, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30596402
14.
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Lancet Oncol
; 17(11): 1569-1578, 2016 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-27646843
15.
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
Biol Blood Marrow Transplant
; 22(2): 380-385, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26348890
16.
A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).
Am J Hematol
; 91(3): 308-12, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26662208
17.
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.
Br J Haematol
; 169(2): 219-27, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25683772
18.
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.
Br J Haematol
; 171(5): 788-97, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-26455717
19.
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
Hematol Oncol
; 33(4): 187-91, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-25236531
20.
A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.
Br J Haematol
; 186(1): 159-162, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30592026